UnitedHealth Group, the nation's largest health insurer with a market capitalization exceeding $400 billion, faces perhaps its most consequential earnings report in years when it releases fourth-quarter 2025 results on Tuesday, January 27. The company's stock has suffered a punishing decline of 34.5% over the past twelve months, sharply underperforming both its industry and the broader market amid escalating concerns about medical cost inflation.

The Medical Cost Ratio Problem

At the heart of UnitedHealth's challenges is the Medical Care Ratio (MCR)—the percentage of premium revenue spent on actual medical claims. This metric has been deteriorating steadily and accelerating in recent quarters:

  • 2022: 82.0% MCR
  • 2023: 83.2% MCR
  • 2024: 85.5% MCR
  • Q3 2025: 89.9% MCR

The trajectory is alarming. Every percentage point increase in MCR represents billions of dollars in additional costs that compress margins and reduce profitability. The Q3 figure of 89.9% leaves precious little room for administrative costs and profit.

"MCR has been a major pain point. The ratio climbed steadily through 2024 and reached levels in Q3 2025 that call into question the company's ability to price risk accurately in this environment."

— Healthcare sector analyst

What Wall Street Expects

Analysts project UnitedHealth will report earnings of $2.09 per share for Q4 2025, representing a year-over-year decline of 69.3%. Revenue is expected to reach $113.26 billion, up 12.4% from the prior year—demonstrating that the company can still grow the top line even as profitability suffers.

For full-year 2025, the consensus estimate stands at $16.30 per share, implying a sharp 41.1% year-over-year decline from 2024's results. This dramatic earnings compression explains the stock's underperformance.

The Drivers Behind Rising Costs

Several factors are contributing to UnitedHealth's medical cost pressures:

  • Medicare Advantage utilization: Seniors enrolled in MA plans are using more services than actuarial models predicted
  • GLP-1 drug costs: Weight-loss medications like Ozempic and Wegovy are adding billions in pharmacy expenses
  • Provider consolidation: Hospital systems with more market power are negotiating higher reimbursement rates
  • Regulatory pressure: Government scrutiny of prior authorization and claims denials may be increasing claim payments
  • Post-pandemic catch-up: Deferred care during COVID continues to flow through the system

Signs of Confidence at the Top

Despite the challenges, there are reasons for optimism. The return of former CEO Stephen Hemsley in May 2025, coupled with his personal stock purchase of more than $25 million, signals management conviction that the situation is manageable.

Perhaps more notably, Berkshire Hathaway disclosed a $1.57 billion investment in UnitedHealth during 2025, suggesting that Warren Buffett's team sees long-term value emerging from current distressed levels. Berkshire's history of investing in quality companies during periods of temporary difficulty lends credibility to the bull case.

2026 Outlook: Cautious Optimism

Looking ahead, analysts expect some improvement in 2026. The consensus estimate for next year's earnings stands at $17.60 per share, reflecting nearly 8% growth from 2025's depressed levels. Revenue is projected to rise 2.2% to $458.04 billion.

The path to recovery likely requires:

  • Premium repricing: Higher rates on 2026 policies to reflect actual cost trends
  • Benefit design changes: Adjusting coverage to better manage high-cost categories
  • Provider negotiations: Pushing back on aggressive rate demands from hospital systems
  • Medicare Advantage optimization: Improving risk adjustment accuracy and care management

What Investors Should Watch Tuesday

When UnitedHealth reports before the market opens on Tuesday, key metrics to monitor include:

  • Q4 Medical Care Ratio: Any improvement from Q3's 89.9% would be encouraging
  • 2026 guidance: Management's outlook for MCR normalization and earnings recovery
  • Optum performance: The health services division that provides diversification from insurance
  • Membership trends: Whether elevated costs are causing customer attrition
  • Capital allocation: Dividend and buyback plans given earnings pressure

The Investment Case

UnitedHealth presents a classic value investing dilemma. The stock trades at a significant discount to its historical multiple, reflecting genuine operational challenges. Bears argue that medical cost inflation may be structural rather than cyclical, permanently impairing the business model.

Bulls counter that UnitedHealth's scale, diversification through Optum, and management's track record of navigating difficult periods make the current valuation compelling for patient investors. The Berkshire investment provides external validation of this thesis.

Tuesday's report won't resolve this debate, but it will provide crucial data points on whether UnitedHealth's cost problems are stabilizing or accelerating. For a company of this size and importance to the healthcare system, the stakes could hardly be higher.